Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Financials ($)
Sales 2016 66,8 M
EBIT 2016 4,47 M
Net income 2016 -9,49 M
Debt 2016 48,8 M
Yield 2016 -
Sales 2017 91,2 M
EBIT 2017 10,9 M
Net income 2017 -2,55 M
Debt 2017 72,1 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 6,13x
EV / Sales2017 4,75x
Capitalization 361 M
More Financials
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
03/07Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
01/19 NASDAQ : TLGT Investor Alert: Investigation over Possible Wrongdoing at Teligent..
01/17 TELIGENT : Biotech Mergers and Acquisitions Could See Significant Rebound
01/16 TELIGENT : Biotech Mergers and Acquisitions Could See Significant Rebound
01/11 TELIGENT : Regulation FD Disclosure (form 8-K/A)
01/11 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Regulation FD Disclosure
01/11 TELIGENT, INC. : Regulation FD Disclosure (form 8-K)
01/10 TELIGENT, INC. : To Present At 35th Annual J.P. Morgan Healthcare Conference On ..
01/04 ROBBINS ARROYO LLP : Is Investigating the Officers and Directors of Teligent, In..
01/03 TELIGENT, INC. : Announces FDA Approval For Three Abbreviated New Drug Applicati..
2016 TELIGENT, INC. : Announces FDA Approval Of Clobetasol Propionate Lotion 0.05%
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 43%
Consensus details
EPS Revisions
More Estimates Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results